mitoxantrone has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 23 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL." | 2.82 | Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. ( Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016) |
| "Gemcitabine (G) has shown activity in mantle cell lymphoma (MCL) as a single agent." | 2.74 | Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. ( Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y, 2009) |
| "Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma." | 2.73 | Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. ( Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M, 2007) |
| "In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades." | 2.72 | Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006) |
| "Usually, thrombocytopenia was not associated with bleeding manifestations." | 2.45 | Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. ( Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O, 2009) |
| "Minimal residual disease was monitored by qualitative and real-time quantitative PCR." | 1.33 | Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. ( Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (82.61) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakai, T | 1 |
| Masaki, Y | 1 |
| Otsuki, N | 1 |
| Sakamaki, I | 1 |
| Kishi, S | 1 |
| Miyazono, T | 1 |
| Urasaki, Y | 1 |
| Murakami, J | 1 |
| Satoh, T | 1 |
| Nakamura, T | 1 |
| Iwao, H | 1 |
| Nakajima, A | 1 |
| Kawanami, T | 1 |
| Miki, M | 1 |
| Fujita, Y | 1 |
| Tanaka, M | 1 |
| Fukushima, T | 1 |
| Okazaki, T | 1 |
| Ueda, T | 1 |
| Shin, DY | 1 |
| Kim, SJ | 1 |
| Yoon, DH | 1 |
| Park, Y | 1 |
| Kong, JH | 1 |
| Kim, JA | 1 |
| Kim, BS | 1 |
| Kim, HJ | 1 |
| Won, JH | 1 |
| Park, SK | 1 |
| Kim, WS | 1 |
| Garbo, LE | 1 |
| Flynn, PJ | 1 |
| MacRae, MA | 1 |
| Rauch, MA | 1 |
| Wang, Y | 1 |
| Kolibaba, KS | 1 |
| Ram, R | 1 |
| Bonstein, L | 1 |
| Gafter-Gvili, A | 1 |
| Ben-Bassat, I | 1 |
| Shpilberg, O | 1 |
| Raanani, P | 1 |
| Takasaki, H | 1 |
| Hashimoto, C | 1 |
| Takemura, S | 1 |
| Motomura, S | 1 |
| Ishigatsubo, Y | 1 |
| Crout, CA | 1 |
| Koh, LP | 1 |
| Gockerman, JP | 1 |
| Moore, JO | 1 |
| Decastro, C | 1 |
| Long, GD | 1 |
| Diehl, L | 1 |
| Gasparetto, C | 1 |
| Niedzwiecki, D | 1 |
| Edwards, J | 1 |
| Prosnitz, L | 1 |
| Horwitz, M | 1 |
| Chute, J | 1 |
| Morris, A | 1 |
| Davis, P | 1 |
| Beaven, A | 1 |
| Chao, NJ | 1 |
| Ali-Osman, F | 1 |
| Rizzieri, DA | 1 |
| Rummel, MJ | 1 |
| Chow, KU | 1 |
| Karakas, T | 1 |
| Jäger, E | 1 |
| Mezger, J | 1 |
| von Grünhagen, U | 1 |
| Schalk, KP | 1 |
| Burkhard, O | 1 |
| Hansmann, ML | 1 |
| Ritzel, H | 1 |
| Bergmann, L | 1 |
| Hoelzer, D | 1 |
| Mitrou, PS | 1 |
| Forstpointner, R | 4 |
| Hänel, A | 3 |
| Repp, R | 3 |
| Hermann, S | 2 |
| Metzner, B | 3 |
| Pott, C | 3 |
| Hartmann, F | 3 |
| Rothmann, F | 2 |
| Böck, HP | 3 |
| Wandt, H | 4 |
| Unterhalt, M | 7 |
| Hiddemann, W | 8 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Fiedler, F | 1 |
| Franke, A | 1 |
| Freund, M | 2 |
| Helbig, W | 1 |
| Pasold, R | 1 |
| Dreyling, M | 7 |
| Gianni, AM | 2 |
| Magni, M | 2 |
| Martelli, M | 1 |
| Di Nicola, M | 1 |
| Carlo-Stella, C | 1 |
| Pilotti, S | 1 |
| Rambaldi, A | 1 |
| Cortelazzo, S | 1 |
| Patti, C | 1 |
| Parvis, G | 1 |
| Benedetti, F | 1 |
| Capria, S | 1 |
| Corradini, P | 1 |
| Tarella, C | 2 |
| Barbui, T | 1 |
| Rohrberg, R | 1 |
| Ferrer, A | 1 |
| Marcé, S | 1 |
| Bellosillo, B | 1 |
| Villamor, N | 1 |
| Bosch, F | 1 |
| López-Guillermo, A | 1 |
| Espinet, B | 1 |
| Solé, F | 1 |
| Montserrat, E | 1 |
| Campo, E | 1 |
| Colomer, D | 1 |
| Robinson, H | 1 |
| Rymes, N | 1 |
| Hanamura, A | 1 |
| Hayakawa, M | 1 |
| Naito, K | 1 |
| Nickenig, C | 2 |
| Hoster, E | 2 |
| Pfreundschuh, M | 1 |
| Trumper, L | 2 |
| Reiser, M | 1 |
| Lengfelder, E | 1 |
| Seymour, JF | 1 |
| Lehmann, T | 1 |
| Einsele, H | 1 |
| Ludwig, WD | 1 |
| Dörken, B | 1 |
| Huber, C | 2 |
| Ganser, A | 1 |
| Ladetto, M | 1 |
| Pagliano, G | 1 |
| De Marco, F | 1 |
| Drandi, D | 1 |
| Ricca, I | 1 |
| Astolfi, M | 1 |
| Matteucci, P | 1 |
| Guidetti, A | 1 |
| Mantoan, B | 1 |
| Bodoni, CL | 1 |
| Zanni, M | 1 |
| Boccadoro, M | 1 |
| Valencak, J | 1 |
| Troch, M | 1 |
| Raderer, M | 1 |
| Weigert, O | 1 |
| Pastore, A | 1 |
| Rieken, M | 1 |
| Lang, N | 1 |
| Weide, R | 1 |
| Hess, G | 1 |
| Köppler, H | 1 |
| Heymanns, J | 1 |
| Thomalla, J | 1 |
| Aldaoud, A | 1 |
| Losem, C | 1 |
| Schmitz, S | 1 |
| Haak, U | 1 |
| Voso, MT | 1 |
| Pantel, G | 1 |
| Weis, M | 1 |
| Schmidt, P | 1 |
| Martin, S | 1 |
| Moos, M | 1 |
| Ho, AD | 1 |
| Haas, R | 1 |
| Hohaus, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.[NCT00354822] | Phase 2 | 25 participants (Actual) | Interventional | 2005-08-31 | Terminated (stopped due to Inability to recruit in time a sufficient number of patients) | ||
| Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only[NCT00317096] | Phase 3 | 319 participants (Actual) | Interventional | 1998-11-30 | Active, not recruiting | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials[NCT06049472] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
14 trials available for mitoxantrone and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
8 other studies available for mitoxantrone and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
| Article | Year |
|---|---|
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Surviva | 2004 |
Extranodal mantle cell lymphoma in a prolapsed ileostomy stump.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Humans; Ileal Neo | 2005 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Edem | 2007 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2000 |